Exemestane (Aromasin)

Exemestane, sold as Aromasin, is a pill you swallow that lowers the body’s estrogen. It is a steroidal third-generation aromatase inhibitor (AI) — a real, well-studied cancer drug. It is worth being clear about what it is and isn’t: exemestane is not a peptide, not a SERM (selective estrogen receptor modulator, the class that tamoxifen belongs to), and not an anabolic steroid. It works by switching off the enzyme (a protein that drives a chemical reaction) that the body uses to make estrogen, which drops estradiol (the main form of estrogen) throughout the body. In breast-cancer care it has a strong track record backed by repeated, published studies. In bodybuilding it gets used off-label (for a purpose the drug was never approved for) to blunt the estrogen that builds up when certain muscle-building hormones are taken — and that use is unapproved, untested in that group of people, banned in sport, and able to cause real harm. This page is here to inform and reduce harm. It contains no doses, cycles, stacks, or post-cycle plans, and no information about where to get the drug.

What it is

Exemestane is a steroidal third-generation aromatase inhibitor. Its chemical structure is built from androstenedione — the natural molecule that the aromatase enzyme normally acts on. The non-steroidal AIs (anastrozole and letrozole) latch onto the enzyme only temporarily. Exemestane is different: it is an irreversible “suicide” inactivator (a Type I inhibitor). The aromatase enzyme grabs it and turns it into a form that locks permanently onto the enzyme’s working part, shutting that enzyme molecule down for good.

Aromatase (also called CYP19) is the enzyme that turns androgens (male-type hormones) into estrogens, so blocking it lowers circulating estradiol. In postmenopausal women and in men, this cuts body-wide estrogen sharply. One important point: exemestane does not block estrogen receptors (the docking sites estrogen plugs into). Blocking those receptors is how SERMs such as tamoxifen work, and that is a completely separate class of drug.

The claims

Medically, exemestane is used for ER-positive breast cancer (both early-stage and advanced disease) in postmenopausal women. In some premenopausal women it is used too, but only alongside treatment that shuts down the ovaries. It has also been studied — but not approved — for lowering the risk of breast cancer in postmenopausal women who are at higher risk.

In the PED (performance-enhancing drug) context — off-label, illegal, and unapproved — people who use anabolic-androgenic steroids (AAS, muscle-building hormones) or prohormones take AIs like exemestane to hold down the estrogen that forms when those hormones get converted into estradiol. The stated goals are to limit gynecomastia (breast tissue growth in men), water retention, and other estrogen-driven side effects, and sometimes to try to bring testosterone back up after a cycle (lowering estrogen raises the signaling hormones LH and FSH, which in turn nudges testosterone up). This is unapproved use with no medical oversight. The human evidence below all comes from cancer patients, not healthy male athletes — so any claims about how well it works or how safe it is for PED use are mostly guesswork and barely studied.

What the evidence actually shows

The cancer evidence is large and solid.

• IES (Intergroup Exemestane Study) — 4,724 postmenopausal women with ER-positive or ER-unknown early breast cancer: switching to exemestane after 2–3 years of tamoxifen improved disease-free survival (how long patients lived without the cancer coming back) — HR ~0.76; 354 vs 455 DFS events. The overall-survival results leaned in exemestane’s favor — 222 deaths (exemestane) vs 261 deaths (tamoxifen), unadjusted HR ~0.85 (95% CI 0.71–1.02) — and became statistically meaningful (HR 0.83) once ER-negative patients were left out. The 10-year follow-up (2017) confirmed a small overall-survival benefit that did not reach statistical significance (HR ~0.89).
• MAP.3 (Goss et al., NEJM 2011) — prevention: in higher-risk postmenopausal women, exemestane lowered the yearly rate of invasive breast cancer (0.19% vs 0.55% with placebo; HR 0.35) — roughly a 65% relative drop over a median follow-up of about 35 months. This showed it can help prevent breast cancer, yet exemestane is still not approved for that use.
• Bone effects (IES skeletal substudy, Coleman 2007): exemestane speeds up the loss of bone-mineral density compared with tamoxifen and is linked to a higher fracture risk. This is a known pattern across the whole AI class, because estrogen helps protect bone.
• Endometrial (the lining of the uterus): unlike tamoxifen, AIs do not stimulate that lining. The IES long-term endometrial data showed exemestane reverses the thickening that tamoxifen can cause and is not tied to the uterine-cancer warning signal seen with tamoxifen.

On PED use specifically: there are no high-quality trials showing exemestane is safe or effective for controlling estrogen in healthy male AAS users. The cancer studies do not back up that practice.

Legal and regulatory status

US — prescription (Rx) drug. Exemestane is legal only with a valid prescription. Selling or handing it out for human bodybuilding use, or labeling it as an unapproved “research chemical,” is illegal. It is not a controlled substance — aromatase inhibitors and SERMs are not scheduled.

To keep things clear, here is how it compares with some drugs that often come up alongside it:

• Mesterolone and fluoxymesterone are anabolic-androgenic steroids — Schedule III controlled substances under the US Controlled Substances Act.
• DNP (2,4-dinitrophenol) is NOT approved for people to consume. The FDA pulled it from the market for human use in 1938; it has a long, documented history of fatal poisonings and is sold illegally as a “fat burner.”
• T3 (liothyronine) and insulin are prescription drugs, not controlled substances, but they are dangerous when misused (see Safety).

Anti-doping (WADA 2026 Prohibited List). Exemestane is prohibited at all times (both in and out of competition) under S4, “Hormone and Metabolic Modulators.”

• S4.1 Aromatase inhibitors — exemestane, anastrozole, letrozole, formestane, testolactone, aminoglutethimide.
• S4.2 Anti-estrogenic substances — anti-estrogens and SERMs (e.g., tamoxifen, raloxifene, clomifene).
• S4.4 Metabolic modulators — includes insulins and insulin-mimetics, plus agents such as AICAR, GW1516, and SR9009/SR9011.

For context: DNP is prohibited under S4.4 as a metabolic modulator (it is named directly on the list). Anabolic steroids (mesterolone, fluoxymesterone, etc.) fall under S1. Thyroid hormone (T3/liothyronine) is not currently on the WADA Prohibited List.

Safety

Most of the harm from exemestane and the rest of the AI class comes down to one thing: too little estrogen.

• Bone: faster loss of bone density, osteoporosis (thin, brittle bones), and a higher fracture risk (documented in IES).
• Lipids / cardiovascular (blood fats and heart/blood vessels): it can shift blood fats in an unhealthy direction, and the AI class is linked to heart and lipid concerns. In men whose estrogen is already low, pushing it down further makes blood fats and bones worse.
• Other: joint aches (common, and sometimes bad enough to force stopping the drug), hot flashes, fatigue, mood changes, low libido and sexual problems (especially in men whose estradiol has been crashed), and raised liver enzymes (a sign of liver stress). In men, estradiol is essential for bone, libido, and healthy blood fats — so “crashing” estrogen with an AI is genuinely harmful, not harmless.

Why experimenting with exemestane in a PED setting is dangerous is largely about the other drugs people combine with it:

• DNP — the deadliest item here. It jams the cell’s energy-making machinery (it “uncouples” oxidative phosphorylation, the process mitochondria use to make energy), so instead of producing usable energy the cell dumps it out as heat. The result is uncontrolled overheating (body temperatures reported as high as ~44 °C / 111 °F), heavy sweating, a racing heart (tachycardia), and multiple organs shutting down. There is NO antidote — all doctors can do is cool the patient and support the body. Many deaths are on record, and the dose that works sits dangerously close to the dose that kills. DNP kills people; it should never be swallowed.
• Insulin: when people without diabetes misuse it for a muscle-building effect, it can cause fast, severe, potentially deadly low blood sugar (hypoglycemia), seizures, permanent brain damage, and death.
• SERMs (tamoxifen, clomifene, raloxifene): a higher risk of blood clots (venous thromboembolism — DVT/PE), and, with tamoxifen, effects on the uterine lining.
• T3 (liothyronine): misusing it can cause irregular or racing heartbeat (arrhythmia, tachycardia, atrial fibrillation), bone loss, and shutdown of the body’s own thyroid control system (the HPT axis) that can linger even after stopping.

Bottom line

Exemestane is a genuine, well-studied cancer drug with a clear evidence base in postmenopausal breast cancer — a steroidal, irreversible aromatase inhibitor, not a peptide and not a SERM. Using it in bodybuilding to manipulate estrogen is off-label, unapproved, untested in that group, banned in sport (WADA S4.1), and carries real risks: bone loss, harm to blood fats and the heart, and the sexual and mood effects of crashing estrogen, which is genuinely harmful in men. And the drugs people pair it with — especially DNP and insulin — can kill.

Evidence grade: 10/10 · Established.

Sources

• Goss PE et al., 2011 — Exemestane for breast-cancer prevention in postmenopausal women (MAP.3), N Engl J Med (PMID 21639806)
• Coombes RC et al., 2007 — Survival and safety of exemestane vs tamoxifen after 2–3 years’ tamoxifen (IES), Lancet (PMID 17307102)
• Jassem J / International Exemestane Study Group, 2008 — IES mature overall-survival analysis, Anticancer Drugs (PMID 18340242)
• Morden JP et al., 2017 — Long-Term Follow-Up of the Intergroup Exemestane Study, J Clin Oncol (PMID 28467729)
• Coleman RE et al., 2007 — Skeletal effects of exemestane on BMD and fracture incidence (IES), Lancet Oncol (PMID 17267326)
• Bertelli G et al., 2010 — Long-term endometrial effects in postmenopausal women in the IES, Ann Oncol 21(3):498-505 (PMID 19717534)
• WADA — The Prohibited List
• USADA — What’s New on the 2026 WADA Prohibited List?
• NCI — Exemestane Reduces Breast Cancer Risk in High-Risk Postmenopausal Women
• 2,4-Dinitrophenol — mechanism, no antidote, 1938 FDA removal, fatalities (Wikipedia)
• Exemestane — mechanism and approval overview (Wikipedia)